Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.68 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424969 | 1.00 | CTSK (0.68) | CTSKACECTSSCA1CA2 | |
| SCHEMBL7426593 | 1.00 | CTSK (0.68) | CTSKACECTSSCA1CA2 | |
| SCHEMBL1433273 | 1.00 | CTSK (0.68) | CTSKACECTSSCA1CA2 | |
| SCHEMBL17870451 | 0.92 | CTSK (0.55) | CTSKACECTSSCA1CA2 | |
| SCHEMBL14242024 | 0.92 | CTSK (0.55) | CTSKACECTSSCA1CA2 | |
| SCHEMBL17870454 | 0.92 | CTSK (0.55) | CTSKACECTSSCA1CA2 | |
| SCHEMBL5967025 | 0.89 | CTSK (0.58) | CTSKACECTSSCA1CA2 | |
| SCHEMBL19003825 | 0.86 | CTSK (0.50) | CTSKACECTSSCA1CA2 | |
| SCHEMBL22412573 | 0.86 | CTSK (0.50) | CTSKACECTSSCA1CA2 | |
| SCHEMBL22412574 | 0.86 | CTSK (0.50) | CTSKACECTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882734-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2880026-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-06-10 | — | — | EP | disclosed |
| US-20150148524-A1 | AMINO ACID ANALOGUES AND METHODS FOR THEIR SYNTHESIS | UNIV MONASH (AU) | 2015-05-28 | — | — | US | disclosed |
| US-8901115-B2 | Cyclic P1 linkers as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2739625-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2014022767-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014022766-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2013022814-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
| US-5665598-A | Synthesis of chiral N-protected-α-substituted-glycine free acids by zinc-mediated addition of organic halide to glycine cation equivalent | G. D. SEARLE & CO. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5508466-A | REACTING MIXTURE OF N-PROTECTED-ALPHA-SUBSTITUTED-GLYCINE CATION DERIVATIVE AND ELEMENTAL ZINC WITH ORGANIC HALIDE IN POLAR SOLVENT | G.D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148524-A1 | AMINO ACID ANALOGUES AND METHODS FOR THEIR SYNTHESIS | DAO, BCAT2, BCAT1 | CTSK 3424/4885ACE 591/4885CTSS 2960/4885 |
| US-20140163002-A1 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS | F11, F12, F13A1 | CTSK 263/4885ACE 1138/4885CTSS 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.